Regorafenib Improves PFS, OS in Asian Patients With mCRC
Treatment with regorafenib significantly improved overall survival (OS) and progression-free survival (PFS) in an Asian population of patients with previously treated metastatic colorectal cancer (mCRC).
Ruxolitinib Combination Improves Survival in Pancreatic Cancer
Adding ruxolitinib (Jakafi) to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation.
Prognostic Scale Emerges for OS in Locally Advanced Pancreatic Cancer
Four independent prognostic factors for improved overall survival (OS) in patients with locally advanced pancreatic cancer (LAPC) emerged from an analysis of the LAP 07 phase III trial.